Trial reportJournal of Korean medical science2014
Prophylactic effect of erythropoietin injection to prevent acute mountain sickness: an open-label randomized controlled trial.
Trial report in Journal of Korean medical science, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- Pooled it
- Interventions for preventing high altitude illness: Part 3. Miscellaneous and non-pharmacological interventions.The Cochrane database of systematic reviews · 2019Pooled it
- Review
- Thioamide Compound H0802 Enhances Hypoxia Tolerance by Mimicking Hypoxia-Adaptive Reprogramming of Glucose and Oxygen Metabolism.Antioxidants (Basel, Switzerland) · 2026Article
- Darbepoetin alpha has an anxiolytic and anti-neuroinflammatory effect in male rats.BMC immunology · 2024Article
- Altitude Pre-Acclimatization with an Erythropoiesis-Stimulating Agent.European journal of case reports in internal medicine · 2023Article
- Low serum erythropoietin levels are associated with fatal COVID-19 cases at 4,150 meters above sea level.Respiratory physiology & neurobiology · 2021Observational
- Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?Respiratory physiology & neurobiology · 2020Review
- Erythropoietin as candidate for supportive treatment of severe COVID-19.Molecular medicine (Cambridge, Mass.) · 2020Review
- Hematological Risk Factors for High-Altitude Headache in Chinese Men Following Acute Exposure at 3,700 m.Frontiers in physiology · 2017Article
- Altitude Stress During Participation of Medical Congress.Neurointervention · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was performed to evaluate whether increasing hemoglobin before ascent by prophylactic erythropoietin injections prevents acute mountain sickness (AMS). This open-label, randomized, controlled trial involved 39 healthy volunteers with hemoglobin ≤ 15.5 g/dL who were divided randomly into erythropoietin (n=20) and control (n=19) groups. Epoetin alpha 10,000 IU injections were given weekly for four consecutive weeks. On day 1, and 7 days after the last injection (day 29), oxygen saturation (SaO2), and hemoglobin were measured. The subjects departed Seoul on day 30 and arrived at Annapurna base camp (ABC, 4,130 m) on day 34. AMS was diagnosed when headache and Lake Louise score (LLS) of ≥ 3 were present. Immediate descent criteria followed US Army recommendations. Two groups differ in hemoglobin levels on day 29 (15.4 ± 1.1 vs 14.2 ± 1.0 g/dL, P=0.001). At ABC, erythropoietin group had a significantly lower mean LLS, AMS incidence, and number of subjects who met immediate descent criteria. Multiple logistic regression analysis showed that SaO2<87% and control group, but not hemoglobin<15.0 g/dL, independently predicted satisfaction of immediate descent criteria. Erythropoietin-related adverse effects were not observed. In conclusion, erythropoietin may be an effective prophylaxis for AMS.(Clinical Trial Registry Number; NCT 01665781).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.